Heart failure & cardiomyopathies
Transthyretin Amyloid Cardiomyopathy Among Patients with Heart Failure and Preserved Ejection Fraction: The AMY Score
Authors' conclusion
A score based on basic clinical and echocardiographic features helps to distinguish ATTRwt-CM from typical HFpEF.
Study context
- Population
- Patients with heart failure with preserved ejection fraction (HFpEF); ATTRwt-CM diagnosed by endomyocardial biopsyATTRwt-CM by biopsy
- Participants
- 60 patients
- Comparison
- AMY score for ATTRwt-CM vs HFpEF
- Outcome
- Accuracy of a weighted point-based score (IVSd > 14 mm = 1; absence of obesity = 2; E/e' > 14 = 3) for predicting ATTRwt-CM
Methodological detailspropensity-score matched, external validation
- Propensity-score matched
- External validation
Performance
As reported in the abstract
Discrimination of ATTRwt-CM from HFpEF (derivation, matched cohort)
| Test or model | Value | P | Sensitivity (score >3 points) | Specificity (score >3 points) |
|---|---|---|---|---|
| Score | AUC 0.91 (CI 0.84–0.97) | P < 0.01 | 78% | 90% |
Score
ValueAUC 0.91 (CI 0.84–0.97)
PP < 0.01
Sensitivity (score >3 points)78%
Specificity (score >3 points)90%
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Transthyretin Amyloid Cardiomyopathy Among Patients with Heart Failure and Preserved Ejection Fraction: The AMY Score. ESC Heart Fail. Published 13 April 2024. doi:10.
Summarised from the published abstract; every number is checked against it